Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1 Study of NTB-928 in R/R OC
Sponsor: TeneoSeven, Inc.
Summary
The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the body, and how the immune system reacts to it. The study will also look for early signs of anti-cancer activity of NTB-928. The main questions the study aims to answer are: * What side effects do participants experience when receiving NTB-928, including side effects that limit how much of it can be safely given? * How is NTB-928 processed by the body at different dose levels? * Does the immune system react to NTB-928 during treatment? * What dose of NTB-928 can be given safely that shows early signs of activity against ovarian cancer?
Official title: A Phase 1 Multicenter, Open-Label, Dose-Escalation and Expansion Study of NTB-928, a FRα-Targeting Bispecific T Cell Engager, in Subjects With Relapsed/Refractory Ovarian Carcinoma
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-06-29
Completion Date
2029-02
Last Updated
2026-07-08
Healthy Volunteers
No
Conditions
Interventions
NTB-928
NTB-928 is an investigational study drug administered as an intravenous infusion.
Locations (2)
START Northwell, LLC
Lake Success, New York, United States
Start Ccbd, Llc
Fort Worth, Texas, United States